GlassScriptPhysician profile
Robert A Moreno
NPI 1174518823
$1,398.37
in general payments reported to CMS, 2019-2025
18 companies · $18.94 in 2025
The $18.94 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $276 · 2021: $255 · 2022: $47.24 · 2023: $361 · 2024: $145 · 2025: $18.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $223.18 | 2019-2021 | |
| Abbott Laboratories | $204.34 | 2021-2023 | Freestyle Libre 3 |
| Abbvie INC. | $198.89 | 2021-2024 | |
| Amgen INC. | $183.52 | 2019 | |
| Allergan, INC. | $147.26 | 2020 | |
| Lilly USA, LLC | $82.84 | 2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.87 | 2020-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $47.52 | 2023 | |
| Insulet Corporation | $45.11 | 2023 | Omnipod |
| Janssen Pharmaceuticals, INC | $34.92 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.45 | 2021 | |
| Janssen Biotech, INC. | $23.63 | 2024 | Simponi Aria, Simponi, Stelara |
| Aurinia Pharma U.S., INC. | $22.97 | 2023 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $21.84 | 2022 | |
| Merck Sharp & Dohme LLC | $18.94 | 2025 | Bridion |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.69 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.92 | 2022 | |
| Alexion Pharmaceuticals, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.